Results 71 to 80 of about 205,719 (255)

Metabolic Dependencies in Pancreatic Cancer. [PDF]

, 2018
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only marginal therapeutic efficacy. FDA approved drugs currently used against
Brody, Jonathan R., Vaziri-Gohar, Ali, Winter, Jordan M., Zarei, Mahsa   +3 more
core   +1 more source

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma [PDF]

, 2018
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
Daylan, Ayse Ece Cali, Del Vecchio, Annachiara, Espinoza, Carlos, Fabo, Tania, Fearon, Eric R., Feng, Ying, Galbán, Stefanie, Halbrook, Christopher J., Karim, Saadia A., Kovalenko, Ilya, Kremer, Daniel M., Kumar-Sinha, Chandan, Lee, Ho-Joon, Ljungman, Mats, Lyssiotis, Costas A., Magnuson, Brian, Morton, Jennifer P., Pasca di Magliano, Marina, Schofield, Heather K., Yan, Wei, Zeller, Jörg   +20 more
core   +1 more source

KRAS inhibitors: going noncovalent

Molecular Oncology, 2022
KRASG12D is the most frequent KRAS mutation in human cancer with particularly high frequencies in pancreatic and colorectal cancer. Informed by the structure of the KRASG12C inhibitor adagrasib, Hallin et al. have now, through multiple rounds of structure‐based drug design, identified and validated a potent, selective, and noncovalent KRASG12D ...
Matthias Drosten, Mariano Barbacid
openaire   +5 more sources

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns, Jaclyn S. Long, Sergio Lilla, Kelly Hodge, Marcus J. G. W. Ladds, Colin Nixon, Paula Fernández‐Palanca, Sara Zanivan, Pilar Acedo, Stephen P. Pereira, Kevin M. Ryan   +10 more
wiley   +1 more source

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population

Biomedical Papers, 2015
Aims: A germline SNP (rs61764370) is located in a let-7 complementary site (LCS6) in the 3'UTR of KRAS oncogene, and it was found to alter the binding capability of the mature let-7 microRNA to the KRAS mRNA.
Magdalena Uvirova, Jarmila Simova, Barbora Kubovaª, Nina Dvorackova, Hana Tomaskova, Monika Sedivcova, Petr Dite   +6 more
doaj   +1 more source

eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]

, 2019
CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina, Foulkes, William D., Fu, Zheng, Guiot, Marie-Christine, Huang, Sidong, Kong, Tim, Monast, Anie, Park, Morag, Pelletier, Jerry, Pilon, Virginie, Porco, John A., Sangwan, Veena, Xue, Yibo, Zhu, Xianbing   +13 more
core   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Molecular mechanisms of resistance and new therapeutic approaches in the treatment of colorectal cancer - a review of the literature

Journal of Education, Health and Sport
CRC occupies one of the leading positions among gastrointestinal malignancies and is a significant problem in Europe since it is the third most frequently diagnosed cancer. Recent developments in diagnostic techniques have led to higher chances of early
Maksymilian Janeczek, Julia Plewniok, Maria Partyka, Julia Wójcik, Karolina Kinga Kantor, Marcin Cholewa, Wiktoria Maria Szymańska, Karolina Jaglarz, Maciej Kuca, Kacper Wojciech Pamuła   +9 more
doaj   +1 more source

Lokalna vodooskrba na Krasu

Dela, 2010
Številni kraški izviri predstavljajo pomembne lokalne vire pitne vode, ki pokrivajo skoraj polovico državnih potreb. Prispevek obravnava način vodooskrbe v preteklosti ter današnje stanje, težave in izzive, s katerimi se soočamo.
Nataša Ravbar
doaj   +1 more source

Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors [PDF]

, 2019
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic ...
Aderka, Dan, García Foncillas, Jesús, Ronga, Philippe, Stintzing, Sebastian, Sunakawa, Yu, Wainberg, Zev, Witzler, Pauline   +6 more
core   +1 more source